ABT
Abbott Laboratories
Revenue by segment
2025, ended Dec 31, 2025
Earlier:
Segments by fiscal year
| USDLine, in USD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | 21.4B | 19.0B | 16.9B | 14.8B | 14.5B | 11.8B | 12.2B | 11.4B | 10.3B | — | — | — | — | — | — | — | — |
| Other | 17M | 16M | 14M | 11M | 52M | 66M | 57M | 62M | 0.24B | 2.39B | 2.27B | 2.47B | 2.50B | 2.46B | 2.60B | — | — |
| 22.9B | 22.9B | 23.2B | 28.8B | 28.5B | 22.8B | 19.6B | 19.1B | 16.8B | 18.5B | 18.1B | 17.8B | 17.2B | 16.6B | 18.8B | 35.2B | 30.8B | |
| Cardiovascular and Neuromodulation Products | — | — | — | — | — | — | — | — | — | 2.90B | 2.79B | — | — | — | — | — | — |
| Reportable Segments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 32.4B | 28.0B |
Diagnostic Products | 8.9B | 9.3B | 10.0B | 16.5B | 15.5B | 10.8B | 7.7B | 7.5B | 5.6B | 4.8B | 4.6B | 4.7B | 4.5B | 4.3B | 4.1B | 3.8B | 3.6B |
Nutritional Products | 8.45B | 8.41B | 8.15B | 7.46B | 8.29B | 7.65B | 7.41B | 7.23B | 6.93B | 6.90B | 6.98B | 6.95B | 6.74B | 6.46B | 5.99B | 5.53B | 5.28B |
Established Pharmaceuticals | 5.54B | 5.19B | 5.07B | 4.91B | 4.72B | 4.30B | 4.49B | 4.42B | 4.29B | 3.86B | 3.72B | 3.12B | 2.86B | 2.77B | 5.36B | 4.46B | 2.94B |
Vascular | — | — | — | — | — | — | — | — | — | — | — | 2.99B | 3.01B | 3.07B | 3.33B | 3.19B | 2.69B |
Proprietary Pharmaceutical Products | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 15.4B | 13.5B |
| Unallocated amount | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.80B | 2.73B |
| Other | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | −279K | −293K |
| Total | 44.3B | 42.0B | 40.1B | 43.7B | 43.1B | 34.6B | 31.9B | 30.6B | 27.4B | 20.9B | 20.4B | 20.2B | 19.7B | 19.1B | 21.4B | 35.2B | 30.8B |